Novo Nordisk Renews GLP-1 Partnership with Hims & Hers, Drops Patent Suit
HIMS sits 89% above its 52-week low of $13.74 on elevated volume (3.8× avg).
Summary
Hims & Hers Health has officially renewed its distribution agreement with Novo Nordisk to provide FDA-approved GLP-1 drugs like Ozempic and Wegovy. This significant development is further bolstered by Novo Nordisk dropping its patent lawsuit against Hims & Hers, removing a major legal and financial overhang. This news confirms the 'nearing a deal' reported on March 9th and solidifies Hims & Hers' position in the lucrative GLP-1 market, following earlier reports of its pharmacy partner resuming compounded GLP-1 sales. The resolution of the lawsuit and the confirmed partnership are highly material positive catalysts, de-risking the company and opening substantial growth avenues. Investors will now closely monitor the operational execution and financial contributions from this expanded GLP-1 offering.
At the time of this announcement, HIMS was trading at $26.02 on NYSE in the Life Sciences sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $13.74 to $70.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.